ORYN 1062
Alternative Names: ORYN-1062Latest Information Update: 08 Sep 2023
At a glance
- Originator Oryn Therapeutics
- Class Antifungals; Antimicrobial cationic peptides; Macrocyclic compounds
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mycoses
Most Recent Events
- 06 Sep 2023 Oryn Therapeutics receives SBIR grant from National Institutes of Health for ORYN 1062 development in Mycoses (multi-drug resistant systemic fungal infection) (Oryn Therapeutics pipeline, September 2023)
- 06 Sep 2023 Oryn Therapeutics has patent protection for OrynotidesTM (Oryn therapeutics website, September 2023)
- 06 Sep 2023 Preclinical trials in Mycoses (multi-drug resistant systemic fungal infection) in USA (Parenteral) (Oryn Therapeutics pipeline, September 2023)